Share AbbVie (ABBV) Q3 2026 Earnings Review: Skyrizi and Rinvoq growth lift profit outlook
← Stock movers news
Earnings results
AbbVieABBV · Drug Manufacturers - General
ABBV · October 30, 2026Before open · Since the previous regular close
-0.31%Session snapshot

AbbVie (ABBV) Q3 2026 Earnings Review: Skyrizi and Rinvoq growth lift profit outlook

Earnings results

  • EPS beat

    Actual: $3.82 adjusted · Cons.: $3.73

  • Revenue beat

    Actual: $17.404B · Cons.: $17.32B

  • Guidance raised

    FY2026 adjusted EPS: $13.95–13.99 vs. $13.76–13.96.

By Stocks To Buy Now AI ResearchPublished

40
AbbVie headquarters building and sign in an archive photograph
Archive photograph of AbbVie headquarters, September 21, 2024. Photograph by LittleT889, CC BY 4.0. Photo: LittleT889 / Wikimedia Commons · CC BY 4.0 · Wikimedia-supplied thumbnail; displayed with a responsive crop.
THE CATALYST

What the company reported

AbbVie raised its annual profit outlook as Skyrizi and Rinvoq growth lifted third-quarter sales, strengthening the case that newer medicines can offset Humira’s decline.

AT A GLANCE

Q3 2026 earnings recap

AbbVie raised its annual profit outlook as Skyrizi and Rinvoq growth lifted third-quarter sales, strengthening the case that newer medicines can offset Humira’s decline.

  • Adjusted profit per share of $3.82 beat the $3.73 estimate, while revenue rose 10.3% to $17.4 billion and exceeded the $17.32 billion forecast.
  • Skyrizi and Rinvoq generated $8.48 billion in combined sales, with both growing more than 22%, while Humira sales fell 31.2%.
  • Neuroscience revenue grew 19.4% to $3.39 billion, adding another growth engine as aesthetics sales slipped 1.4%.
  • The annual adjusted profit forecast rose to $13.95–13.99 per share from $13.76–13.96, including research and licensing charges already incurred.
  • AbbVie increased its quarterly dividend to $1.82 from $1.73 starting in February 2027, a 5.2% rise in shareholder income.
  • At the October 29 close, shares cost about 21 times the new adjusted profit outlook, with chart support around $281–285 and resistance at $291–293.

The next test is whether new medicine launches and continued immunology growth can sustain margins while competition, acquisition costs and Humira’s decline remain risks.

THE VISUAL RESEARCH

Financials, technicals and earnings

Charts through Oct 29, 2026.

Financials
Technicals
Earnings & peers
WHAT TO WATCH

Technical setup and risks

Skyrizi and Rinvoq growth supports higher annual profit guidance; the October 29 chart faces resistance around $291–293 with support near $281–285.

AI-assisted earnings research with verified issuer results. Charts use the stated completed session. Educational information; investing involves risk.

EXPLORE COMPANY RESEARCH

AbbVie: the full stock picture

Earnings history, financials, price action and peer comparisons — all below.
Open ABBV stock page ↗

EXPLORE THE COMPANY

AbbVie (ABBV)

Explore earnings, price action, financials and industry comparisons.

Symbol
ABBV
Sector
Healthcare
Industry
Drug Manufacturers - General
Instrument type
EQUITY

Profile information from our saved company catalog. This is not a live quote or confirmation of current listing status.

EARNINGS & COMPANY RESEARCH

ABBV earnings, valuation & price action

View in calendar ↗
NEXT EXPECTED REPORTOct 30 2026Before open · ET
EPS ESTIMATE3.73
REVENUE ESTIMATE17.32B

Expected dates may change. Estimates use the source’s reporting currency. Quotes and research are snapshots, not live prices.

COMPANY RESEARCH · Healthcare

AbbVie Inc. ABBV

Drug Manufacturers - General · Updated 10/29/2026

Adjusted closing price · USD290.97 Oct 29
186223260297Oct 28Apr 30Oct 29
Price50-day average200-day average+31.7% in view
VALUATION & EXPECTATIONS
Trailing P/E80.4×
Forward P/E20.9×
Trailing P/S7.8×
Forward P/S7.5×
EPS beat rate88%
Revenue beat rate100%
Positive window63%

EPS beats: 7 of 8 comparable reports. Positive price windows: 5 of 8.

Market caps may be up to 14 days old; prices up to seven days old; ratios and analyst estimates up to fourteen days old. Forward multiples use consensus for the fiscal year ending 2026-12-31, not the next 12 months. Negative or unavailable earnings multiples show “N/A”. Forward ADR multiples are omitted when the currency/share basis is not reconciled.

50-day average267.38
200-day average233.85
RSI (14)70
20-day range258.34 – 289.08
Relative volume0.8×
1-year change+31.7%
Last eight reported earnings for ABBV
Report dateEPS estimateEPS actualSurpriseResultRevenue actualPrice window*5 sessions*
Jul 31 20263.613.65+1.1%Beat16.99B-4.8%-4.4%
Apr 29 20262.592.65+2.3%Beat15B+6.9%+3.7%
Feb 4 20262.652.71+2.3%Beat16.62B-2.9%-2.2%
Oct 31 20251.771.86+5.1%Beat15.78B-7.1%-4.0%
Jul 31 20252.882.97+3.1%Beat15.42B+3.1%+5.0%
Apr 25 20252.382.46+3.4%Beat13.34B+6.6%+10.0%
Jan 31 20252.982.16-27.5%Miss15.1B+8.2%+8.5%
Oct 30 20242.923.00+2.7%Beat14.46B+7.6%+6.2%

*Adjusted close before the report date to the first (or fifth) trading close after it. This window can span two sessions and is not an isolated earnings-day return. Figures may be revised by the provider.

More ABBV research Data,

ABBV earnings previews and market catalysts

AbbVie October 30, 2026 earnings preview: growth medicines and research charges
2026-10-28 · AbbVie reports before open on October 30. Watch Skyrizi and Rinvoq sales, Humira erosion and whether the outlook changes beyond research charges already disclosed.

Earnings week of October 26–30, 2026: cloud growth, consumers and cash flow
2026-10-25 · Microsoft, Alphabet and Amazon lead a busy earnings week. Follow twelve major reports across payments, medicine, energy and consumer goods, with the key business questions and risks to watch.

All upcoming earnings catalysts →

02 / FINANCIALS

AbbVie financials

Revenue, earnings, cash flow and financial strength in one view.

Reporting currency unconfirmed.

Revenue
Net income
Gross profit
Operating income
EBITDA
Operating cash flow
Capital expenditure
Cash
Total assets
Total liabilities
Shareholder equity
Total debt
Net profit margin
Gross margin
Short interest: days to cover
How to read these financial metrics

Figures use the app’s saved statements for the displayed period, not a trailing-year total. Margins divide profit by revenue; quick ratio uses current assets less inventory divided by current liabilities. Compare dates and currencies before comparing companies.

03 / WHAT COMES NEXT

AbbVie event catalysts

Company earnings and scheduled market events that may change expectations.

2026-10-30

ABBV earnings

Watch reported results, management’s outlook and the share-price reaction.

See earnings expectations ↑
2026-10-308:30 AM ET

Employment Cost Index

Persistent compensation pressure can affect margins and the inflation outlook.

Release schedule ↗Scheduled
2026-10-30Market close

Russell indexes · rank day

A ranking checkpoint, not an announcement that a particular stock has been included.

Release schedule ↗Scheduled
2026-11-0210:00 AM ET

ISM manufacturing PMI

Watch new orders and prices paid for the balance between demand and inflation.

Release schedule ↗Scheduled
2026-11-0310:00 AM ET

JOLTS job openings

Watch vacancies and quits for signs of labor-market cooling.

Release schedule ↗Scheduled
2026-11-0410:00 AM ET

ISM services PMI

Services prices and employment can influence the outlook for inflation and rates.

Release schedule ↗Scheduled
2026-11-058:30 AM ET

Initial jobless claims

Use the multiweek trend to distinguish normal volatility from a sustained increase in layoffs.

Release schedule ↗Scheduled
2026-11-068:30 AM ET

Jobs report · payrolls & unemployment

Read revisions and wages alongside the headline. Strong hiring can support demand but also lift rate expectations.

Release schedule ↗Scheduled
2026-11-0610:00 AM ET

Consumer sentiment · preliminary

Watch changes in inflation expectations as well as sentiment.

Release schedule ↗Scheduled

Dates use U.S. Eastern time and can change. Calendar events provide context; they do not determine the direction of a stock move.

04 / SIDE BY SIDE

Compare ABBV with its peers

Drug Manufacturers - General · Compare valuation, financial strength and price performance.

Companies with valuation data7
Peer median positive P/E25.8×
ABBV P/E80.4×
ABBV peer comparison: valuation
CompanyPriceMarket capP/EForward P/EP/SForward P/S
ABBVAbbVie2026-10-29 · USD290.97504.37B80.4×20.9×7.8×7.5×
AMGNAmgen Inc.2026-10-29 · USD457.65237.31B27.1×19.9×6.2×6.1×
AZNAstraZeneca PLC2026-10-29 · USD174.40256.53B24.5×4.2×
BMYBristol-Myers Squibb Company2026-10-29 · USD61.39125.76B13.6×9.7×2.6×2.5×
GSKGSK plc2026-10-29 · USD48.68101.97B15.6×2.3×
JNJJohnson & Johnson2026-10-29 · USD275.20663.03B41.8×24.8×6.7×6.6×
LLYEli Lilly and Company2026-10-29 · USD1,373.701.18T41.8×39.8×14.8×13.3×
ABBV80.4×
AMGN27.1×
AZN24.5×
BMY13.6×
GSK15.6×
JNJ41.8×
LLY41.8×

The peer median excludes the selected stock and is based on 6 available positive multiples. P/E median excludes negative or missing earnings multiples. Peer reports can have different fiscal periods and currencies; values are not currency-converted.

05 / PEER ANALYSIS

Explore ABBV alongside its peers

Drug Manufacturers - General · 15 companies · Cached market data

Comparison

Compare companies

Tap a bubble to inspect a company, then × to hide it. Undo restores the last company hidden. Bubble area reflects market cap, with a minimum size for visibility.

Price / sales
0.8×05.9×434.86B11.1×869.73B16.3×1.3TLLY · Eli Lilly and Market cap: 1.18T Price / sales: 14.8×JNJ · Johnson & Johnson Market cap: 663.03B Price / sales: 6.7×MRK · Merck & Market cap: 368.87B Price / sales: 5.6×NVS · Novartis AG Market cap: 285.49B Price / sales: 5.2×AZN · AstraZeneca Market cap: 256.53B Price / sales: 4.2×AMGN · Amgen Market cap: 237.31B Price / sales: 6.2×GILD · Gilead Sciences Market cap: 194.07B Price / sales: 6.4×NVO · Novo Nordisk A/S Market cap: 174.65B Price / sales: 3.5×PFE · Pfizer Market cap: 171.62B Price / sales: 2.7×BMY · Bristol-Myers Squibb Market cap: 125.76B Price / sales: 2.6×GSK · GSK plc Market cap: 101.97B Price / sales: 2.3×ABBV · AbbVie Inc. Market cap: 504.37B Price / sales: 7.8×Hide ABBV · Undo restores itMarket cap
ABBVAbbVie Inc.

Market cap: 504.37B
Price / sales: 7.8×

Valuation snapshot: 2026-10-29
View research ↗
12 of 15 companies have both plotted values.

P/S distribution

Trailing price-to-sales multiples · 12 companies

Median P/S5.4×
Middle 50%3.3× to 6.4×
ABBV P/S7.8×
ABBV
2.0×8.2×

Tap a bar to see the companies in that P/S range. ABBV has a higher P/S than 83% of this group.

3 companies excluded from P/S statistics because sales are non-positive or the saved multiple is missing. Statistics include all valid positive values, including those outside the focused chart range.

Companies

Showing 8 of 15 matching companies · Largest market cap first

  • Market cap 1.18TP/E 41.8×P/S 14.8×Forward P/E Forward P/S Price snapshot: 2026-10-29
    ↗
  • Market cap 663.03BP/E 41.8×P/S 6.7×Forward P/E Forward P/S Price snapshot: 2026-10-29
    ↗
  • Market cap 504.37BP/E 80.4×P/S 7.8×Forward P/E Forward P/S Price snapshot: 2026-10-29
    ↗
  • Market cap 368.87BP/E 118.7×P/S 5.6×Forward P/E Forward P/S Price snapshot: 2026-10-29
    ↗
  • Market cap 285.49BP/E 22.8×P/S 5.2×Forward P/E Forward P/S Price snapshot: 2026-10-29
    ↗
  • Market cap 256.53BP/E 24.5×P/S 4.2×Forward P/E Forward P/S Price snapshot: 2026-10-29
    ↗
  • Market cap 237.31BP/E 27.1×P/S 6.2×Forward P/E Forward P/S Price snapshot: 2026-10-29
    ↗
  • Market cap 194.07BP/E P/S 6.4×Forward P/E Forward P/S Price snapshot: 2026-10-29
    ↗

Explore industries

Open an industry for its comparison, valuation and companies.

U.S.-listed companies from the app’s catalog. Medians use saved positive P/E values; coverage and snapshot dates vary.

How this comparison works

Uses the saved companies from the same industry and listing market, including ABBV, ordered by cached market cap. Company snapshots can have different dates; the web cache may cover fewer metrics and periods than the app.

Periods end at each company’s dated price snapshot. Change compares the latest saved observation with one at or before the selected period’s start. A daily price change uses consecutive saved sessions. Financial data updates quarterly, so short periods may show no change. Missing history and zero starting values are excluded; a negative starting value uses its absolute value as the denominator.

Metrics use saved ratios and percentages. Market caps use the listing market’s reporting currency; underlying financial statements may use different currencies. Circle sizes have a minimum for touch visibility, and an outlined circle indicates a missing market cap. These comparisons describe data, not recommendations or price predictions.

Related research

Company research, movers, earnings and options results.

INDUSTRY COMPARISON

ABBV industry peers

Drug Manufacturers - General · Oct 16, 2026 · Closing-price performance

Compare ABBV with 7 other stocks in the available heatmap coverage.

JNJJohnson & Johnson+0.90%ABBVCurrent stockAbbVie Inc.+0.71%MRKMerck & Co., Inc.+0.52%PFEPfizer Inc.+0.48%LLYEli Lilly and Company+0.43%AMGNAmgen Inc.-0.35%GILDGilead Sciences, Inc.-0.75%BMYBristol-Myers Squibb Company-1.35%